Chemotherapy versus monitoring for positive cancer DNA
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares the effects of a combination of two chemotherapy drugs (CAPEOX) versus close monitoring (active surveillance) in early-stage colorectal cancer patients who have a positive MRD blood test after surgery. The goal is to see if giving chemotherapy can reduce the risk of cancer returning compared to just watching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage I or stage II colorectal cancer that was removed by surgery.
- You were not given chemotherapy or radiation before your surgery.
- A blood test 7 to 21 days after surgery found cancer DNA (called MRD).
- You are generally healthy (able to do light activity) and have no major organ problems.
- You have not had another cancer in the last 3 years and have never had a transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
This study tests whether a special blood test (looking for cancer DNA) can help doctors decide if you need chemotherapy after colorectal cancer surgery. The goal is to avoid unnecessary chemotherapy while making sure patients who need it get treated.
This study compares two different chemotherapy combinations given after surgery to prevent cancer from coming back in people with colorectal cancer who have minimal residual disease (MRD), meaning there are still tiny traces of cancer DNA in the blood. A more intense regimen may work better for this group, and the trial checks if it is safe and more effective.
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
This trial is for people with early-stage colon cancer (stage II high-risk or stage III low-risk) that is not MSI-H. It uses a blood test (MRD) to see if you can safely delay or skip extra chemotherapy after surgery, based on whether the test finds any leftover cancer cells.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.